INTRODUCTION
============

A complex interplay between the renal and cardiovascular systems exists in both health and disease. In humans, the pathological interactions between these two organ systems are increasingly deserving of further definition, classification and understanding. The term "cardiorenal syndrome (CRS)" defined as "disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other" (Ronco *et al*. [@b129]) has been adopted by physicians to describe this pathological interplay. CRS is subdivided into the following five types: type 1, involving acute worsening of heart function leading to kidney injury, such as that occurring in patients with acute congestive heart failure (CHF); type 2, involving chronic disease of the heart leading to kidney injury, such as that occurring in patients with chronic heart failure; type 3, involving acute worsening of kidney function leading to heart injury, such as that in patients with acute kidney injury (AKI); type 4, involving chronic kidney disease (CKD) leading to heart injury; and finally, type 5, involving systemic disease(s) leading to simultaneous injury of both the heart and kidney, such as that occurring in patients with sepsis, systemic hypertension or amyloidosis (Ronco *et al*. [@b129]). Although the epidemiology, diagnosis, prevention and management of CRS in humans have been proposed (Ronco *et al*. [@b129], McCullough *et al*. [@b101], Braam *et al*. [@b16], Ronco & Di Lullo [@b127]), the clinical relevance, time course of onset and pathophysiological mechanisms of CRS are incompletely understood (Braam *et al*. [@b16]). The only recognised facts are (i) blood volume, vasomotor tone and haemodynamic stability are dependent on the cardiovascular and renal systems and (ii) the interactions between the two systems (Bock & Gottlieb [@b12]). The concept of CRS combines the cardiovascular system and kidneys as part of a single homeostatic cardiorenal axis, which challenges cardiologists and nephrologists who treat heart and kidney failure, respectively, to consider this in a complete perspective.

Although kidney and heart diseases are commonly recognised in domestic dogs (Detweiler & Patterson [@b41], Buchanan [@b19], Beardow & Buchanan [@b8], Polzin [@b120], [@b121]) and cats (Buchanan [@b19], Riesen *et al*. [@b125], Chakrabarti *et al*. [@b23]) as an important source of morbidity and mortality (Fleming *et al*. [@b50]), the interaction between the two systems has yet to be formally defined and described by the veterinary profession. The CRS Consensus Group, comprising 16 academic and clinical experts, including 9 veterinary cardiologists and 7 veterinary nephrologists from Europe and North America, was created with the goal of developing consensus, definitions and recommendations for CRS in dogs and cats. The panelists were chosen based on expertise in the areas of cardiology, hypertension and nephrology and recognition as contributing experts in their respective fields. The group was intentionally selected as representative of academic veterinarians from Western Europe and North -America, based on their ability and interest in participating in this project and diplomate status in one or more of the clinical specialties (American and European Colleges of Veterinary Internal Medicine \[ACVIM, ECVIM, respectively, or the European College of Veterinary Clinical Pathology and Toxicology). Other criteria involved in this selection process included past participation in related consensus statement development (International Renal Interest Society \[IRIS\], ACVIM Hypertension Consensus Statement and ACVIM Consensus Statement on Diagnosis and Treatment of Canine Mitral Valve Disease). An advanced degree and/or research experience in nephrology/cardiology were also considered to be desirable attributes. All authors are board-certified and are currently involved in research in their area of specialty, and 10 of 16 have advanced degrees (3 MS, 6 PhD, 1 MD).

The objectives of the group were to 1) define CRS as it pertains to the dogs and cats as veterinary patients, 2) recommend diagnostic testing and evaluation of CRS, 3) provide general guidelines for the treatment of patients with CRS with an emphasis on the potential interplay between the two organ systems and 4) to increase awareness of CRS as an important disease entity in veterinary medicine deserving of further research. Early on, the CRS Consensus Group chose to refer to CRS in veterinary patients as "cardiovascular-renal disorders (CvRD)", such that the vasculature as well as the heart was included, and because, based on experience in cardiovascular and renal diseases, the clinical manifestations of CvRD in the dog and cat are expected to be widely varied among individuals and between species, precluding their description as a single clinical syndrome.

It is important to emphasise that the manifestations of cardiac and renal diseases differ between species, thereby limiting the validity of deriving information from human data for veterinary application, as well as comparisons between dogs and cats. Cardiac disease in humans is primarily related to hypertension and coronary artery disease, which is different from dogs (−primary valvular disease, dilated cardiomyopathy and heartworm disease) and cats (hypertrophic cardiomyopathy, other myopathies and, to a lesser degree, systemic hypertension). Likewise, human renal diseases (glomerular disease, diabetic nephropathy, hypertensive nephropathy, nephrosclerosis, interstitial nephritis and polycystic kidney disease (Maschio *et al*. [@b100], Hou *et al*. [@b70])) do not correlate exactly to those seen in veterinary patients (dogs: glomerular disease, pyelonephritis, acute tubular necrosis, tubulointerstitial disease (Macdougall *et al*. [@b93]) and cats: idiopathic chronic end-stage kidney disease, most often characterised by tubulointerstitial fibrosis, typically of unknown origin (Chakrabarti *et al*. [@b23])). Nevertheless, there are some aspects of the diseases and their pathophysiology that warrant interspecies comparison and application of human findings to veterinary medicine.

METHODOLOGY
===========

The CRS Consensus Group included a 5-person steering and publication committee, comprising a chairman (JLP) and 4 additional steering members (CEA, CB, MAO, SLV), as well as an 11-member rating group. The chairman and steering group oversaw a PubMed search for relevant biomedical literature, published between 1995 and 2013. The committee then drafted a review of CvRD that included 13 summary statements. The 13 statements spanned four different subtopics, including definition, classification and pathophysiology (Subgroup 1--2 statements); epidemiology, clinical aspects and diagnosis (Subgroup 2--3 statements); biomarkers and imaging (Subgroup 3--5 statements); and management (Subgroup 4--3 statements) of CvRD. The literature review and statements were discussed during a 2-day meeting of the entire CRS Consensus Group in April 2013. During this meeting, the entire CRS Consensus Group revised the documents and summary statements to coalesce around points of agreement.

The ultimate goal of the CRS Consensus Group was to produce a consensus document describing CvRD in the dog and cat. A modified Delphi method, based on guidelines by the Haute Autorité de santé (HAS or French National Authority for Health) (Haute Autorité de Santé [@b67]), was utilised to evaluate whether or not each of the 13 draft summary statements achieved formal consensus. According to the method, each group member scored each statement from 1 to 9, depending on the strength of their agreement with the statement, with 1 being that the statement is totally inappropriate, 9 being the statement is totally appropriate and 5 being undecided. Among the 16 rating scores, the lowest and highest scores for each statement were discarded. This resulted in 14 scores, such that no score could be \<5 and the median value must have been ≥7 in order for a statement to be described as having achieved consensus. Two rounds of consensus rating were performed. At the start of the 2-day meeting, group members were introduced to the rating method and they discussed and modified the statements. Following this discussion, the first round of rating was conducted and scores for each statement were reviewed. Then, the group broke out into four different subgroups, each of which were led by a steering committee member (Subgroup 1: CEA, VLF, JE; Subgroup 2: CB, VC, DJP, AMV; Subgroup 3: SLV, JDB, NVI, GFG; Subgroup 4: MAO, TF, LDC, NSM) with the task of revising the statements, based on the results and feedback from the first round of rating. Subsequently, the entire group reconvened for further discussion and revision, and by the end of the meeting, final wording for each of the 13 statements had been constructed. Over the next several weeks, members were able to further consider the statements, using a web-based platform accessible to all the 16 members. Eight weeks after conclusion of the meeting, a second and final round of rating was carried out, using the online platform, with identical rating instructions, scoring procedures and criteria for consensus. For those statements that achieved consensus, the strength of consensus was determined by the lowest value of the 14 individual rating scores, wherein strong consensus was defined as having a lowest individual score ≥7 and good consensus defined as a lowest individual score of either 5 or 6. The final rating results, statements and supporting information were compiled into a draft manuscript by the steering committee, which was then reviewed and edited by all group members before submission for publication.

RESULTS
=======

Definition, classification and pathophysiology of CvRD
------------------------------------------------------

> **Statement 1:** Cardiovascular-renal disorders (CvRD) are defined as disease, toxin or drug-induced structural and/or functional damage to the kidney and/or cardiovascular system, leading to disruption of the normal interactions between these systems, to the ongoing detriment of one or both. (Good consensus; median -rating, 8; range 5--9)
>
> **Statement 2:** CvRD includes subgroups CvRD~H~, CvRD~K~ and CvRD~O~ to reflect renal disease/dysfunction emanating from a disease involving the cardiovascular system; cardiovascular disease/dysfunction secondary to renal disease and concurrent impairment of both systems caused by concurrent primary cardiovascular and kidney disease or "other" disease processes, drugs, toxins or toxicants that affect both systems, respectively. The three categories can be further subdivided into stable disease (S) or unstable disease (U) based on the patient\'s clinical presentation. (Good consensus; median -rating, 7; range, 6--9)

Each of these two statements achieved good consensus. A key concern of both CRS and CvRD is the way the kidney and cardiovascular systems interact, including the potential for harm along three different axes, from kidney to cardiovascular system, from cardiovascular system to kidney and from outside disease processes to both. In instances where disease coexists in both organ systems, it can be difficult to determine the directionality of CvRD or if concurrent primary disease coexists. The concept of CvRD emphasises the inter-related functions of the two organ systems and encourages a complete and early investigation of the function of the heart in instances of kidney disease and the function of the kidney in instances of heart disease. In human medicine, CRS is a relatively new, but evolving, field of medical study, while the understanding of the inter-relationship in animals (CvRD) is in its infancy. Therefore, it is expected that the proposed definition and classification scheme for CvRD in dogs and cats will require reassessment and modification as more veterinary research involving CvRD is performed.

Epidemiology, clinical aspects and diagnosis of CvRD
----------------------------------------------------

> **Statement 3:** Despite the lack of specific data regarding the pathophysiology of CvRD in veterinary medicine, available literature suggests the likelihood that CvRD pathophysiology in animals shares some common patterns with human CRS, namely, the complex interplay of haemodynamic changes, neurohormonal activation and reactive oxygen species, to name a few. (Good consensus; median rating, 8; range, 5--9)

This statement achieved good consensus. The understanding of CRS in humans is incomplete (Ronco & Di Lullo [@b127]), and in veterinary medicine, the existence and exact nature of CvRD is largely speculative. Nevertheless, there are known disease aetiologies in the dog and cat that are characterised by detrimental interactions between the kidney and cardiovascular systems (Table [1](#tbl1){ref-type="table"}). The concept of CRS, which involves a bidirectional pathway of injury wherein disease of either organ directly or indirectly contributes to injury of the other ([Fig 1](#fig01){ref-type="fig"}), presents a broader view of fluid and haemodynamic homeostasis compared to a more traditional viewpoint, which considers kidney and cardiovascular impairment as separate pathophysiological entities. In the following section, the epidemiology and pathophysiology of each of the three classes of CvRD will be discussed.

###### 

Aetiology of cardiovascular-renal disorders (CvRD) in dogs and cats

  CvRD class                                                                                                                                       Aetiology
  ------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CvRD~H~                                                                                                                                          Systemic hypertension leading to glomerular disease
  Cardiac shock, low cardiac output and systemic hypotension leading to decreased renal perfusion, azotaemia and acute kidney injury               
  Systemic arterial thromboembolism leading to renal infarction                                                                                    
  Heartworm infection or caval syndrome leading to glomerulonephritis or AKI, respectively                                                         
  Passive congestion of the kidney during heart failure[\*](#tf1-1){ref-type="table-fn"}                                                           
  CvRD~K~                                                                                                                                          Kidney-mediated systemic hypertension leading to increased afterload, left ventricular hypertrophy, worsening mitral or aortic insufficiency, arrhythmias, vasculopathy or retinopathy
  Volume overload leading to congestion or systemic hypertension                                                                                   
  Hypokalaemia or hyperkalaemia leading to cardiac arrhythmias                                                                                     
  Reduced renal clearance of drugs (e.g. digoxin) leading to toxicity                                                                              
  Uraemic hypodipsia, anorexia or emesis leading to volume depletion and reduced cardiac output and perfusion                                      
  Uraemic pericarditis                                                                                                                             
  Activation of the renin-angiotensin-aldosterone axis leading to sodium and water retention, cardiac and vascular remodelling or congestion       
  Anaemia secondary to chronic kidney disease leading to volume overload and reduced cardiac tissue oxygenation[\*](#tf1-1){ref-type="table-fn"}   
  CvRD~O~                                                                                                                                          Septic or neoplastic emboli leading to renal and cardiac infarction
  Gastric dilation and volvulus leading to cardiac arrhythmias and azotaemia                                                                       
  Infectious disease (e.g. *Trypanosoma cruzi*)                                                                                                    
  Glycogen storage disease leading to glycogen deposition in the kidneys and heart                                                                 
  Amyloidosis leading to amyloid deposition in the kidney and cardiac tissues[\*](#tf1-1){ref-type="table-fn"}                                     

Causes that are proposed, possible or suspected. See text for description of the different CvRD classes.

![Postulated mechanisms underlying the relationship between heart failure (HF) and renal dysfunction. Blue arrows indicate pathways by which HF may lead to renal failure. Red arrows indicate pathways by which renal failure may lead to HF. The relative importance of these mechanisms (and additional mechanisms not discussed) is not known (i.e. boxes are not drawn to scale). The figure has been modified to include systemic hypertension, an important vascular component to CvRD. From Bock. JS. Gottlieb, SS. 2010, adapted with permission. GFR, glomerular filtration rate, RAAS, renin-angiotensin-aldosterone system, SNS, sympathetic nervous system.](jsap0056-0537-f1){#fig01}

### Epidemiology and pathophysiology of CvRD~H~

CvRD~H~ refers to kidney injury or dysfunction emanating from a primary disease process involving the cardiovascular system. Potential mechanisms of CvRD~H~ include decreased kidney perfusion secondary to decreased cardiac output; activation of neuroendocrine systems, namely, the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS); generation of reactive oxygen species by abnormal or injured endothelial tissue and passive venous congestion of the kidney (Table [1](#tbl1){ref-type="table"}) (Haase *et al*. [@b63], McCullough *et al*. [@b101]). Acute reduction in cardiac output can lead to decreased glomerular filtration rate (GFR), increased serum creatinine and blood urea nitrogen (BUN) and decreased urine output (Liang *et al*. [@b89]). In both humans and animals, increases in creatinine as little as 0 · 3 mg/dL (26 · 5 µmol/L) are regarded as indicative of AKI (Jose *et al*. [@b77], Harison *et al*. [@b66], International Renal Interest Society [@b71]). The IRIS has proposed diagnostic criteria for AKI in dogs and cats (Table [2](#tbl2){ref-type="table"}) (International Renal Interest Society [@b71]). This grading system encompasses a continuum of functional and parenchymal damage from its least to its most severe -manifestations. The clinical presentation of AKI includes prerenal and postrenal conditions that may be independent or combined with intrinsic renal injury depending on the functional origin, extent and duration of the conditions inciting the disease. Mild AKI, defined as a serum creatinine concentration \>1 · 6 mg/dL (1 · 7--2 · 5; \>141 µmol/L; 142--220), is detected in dogs or cats treated for heart failure (Goutal *et al*. [@b60]). These relatively modest values, even when they fail to exceed the relevant -laboratory -reference range, if sustained, have been shown to worsen outcome in humans with heart disease (Jose *et al*. [@b77]) and in dogs and cats with various underlying disease processes (Harison *et al*. [@b66]). Whether these changes indicate permanent structural renal damage remains to be determined in dogs and cats. The authors recommend that when treating animals with acute CHF, the lowest diuretic dosage required to resolve signs of congestion should be prescribed and renal values carefully assessed. However, there is no robust evidence that the development of a serum creatinine of \>1 · 6 g/dL (\>141 µmol/L) in cats and dogs with heart failure results in poor clinical outcomes. This would require an adequately powered prospective clinical trial that has not been undertaken. As such, a serum creatinine of \>1 · 6 g/dL (\>141 µmol/L) should not be used as an indicator to withhold necessary therapy in a patient with poorly controlled heart failure.

###### 

International Renal Interest Society (IRIS) grading criteria for acute kidney injury (AKI) in dogs and cats (adapted with permission from Borgarelli *et al*. ([@b14])

  AKI grades                                                                                                                                                                                    Serum creatinine                        Clinical description
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- -------------------------
  I                                                                                                                                                                                             \<1 · 6 mg/dL (\<140 µmol/l)            Non-azotaemic AKI:
  a\. Documented AKI: (Historical, clinical, laboratory or imaging evidence of acute kidney injury, clinical oliguria/anuria, volume responsiveness[†](#tf2-1){ref-type="table-fn"})...and/or                                           
  b\. Progressive *non-azotaemic* increase in serum creatinine; ≥0.3 mg/dL (≥ 26.4 µmol/l) within 48 hours                                                                                                                              
  c\. Measured oliguria (\<1 ml/kg/hr) or anuria over 6 hours                                                                                                                                                                           
  II                                                                                                                                                                                            1 · 7--2 · 5 mg/dL (141--220 µmol/L)    Mild AKI:
  a\. Documented AKI and static or progressive azotaemia                                                                                                                                                                                
  b\. Progressive azotaemic increase in serum creatinine; ≥0.3 mg/dL (≥ 26.4 µmol/l) within 48 hours), or volume responsiveness[†](#tf2-1){ref-type="table-fn"}                                                                         
  c\. Measured oliguria (\<1 ml/kg/h) or anuria over 6 hours                                                                                                                                                                            
  III                                                                                                                                                                                           2 · 6--5 · 0 mg/dL (221--439 µmol/L)    Moderate to severe AKI:
  a\. Documented AKI and increasing severities of azotaemia and functional renal failure                                                                                                                                                
  IV                                                                                                                                                                                            5 · 1--10 · 0 mg/dL (440--880 µmol/L)   
                                                                                                                                                                                                                                        
  V                                                                                                                                                                                             \>10 · 0 mg/dL (\>880 µmol/L)           
                                                                                                                                                                                                                                        

Each grade of AKI is further sub-graded on the basis of oliguria, non-oliguric (NO) or oligoanuria (O), as well as any requirement for renal replacement therapy (RRT).

Volume responsive is an increase in urine production to \>1 ml/kg/h over 6 hours; and/or decrease in serum creatinine to baseline over 48 hours)

In humans, additional mechanisms beyond a decreased cardiac output and glomerular pressure are known to lead to kidney injury. The hydrostatic glomerular filtration gradient, defined as the difference between glomerular blood pressure and capsular hydrostatic pressure, is heavily influenced by systemic venous pressure. Congestion of kidney tissue, due to poor cardiac function and elevated systemic venous pressure, preferentially increases capsular pressure, decreases glomerular filtration pressure and rate and substantially decreases kidney function (Dupont *et al*. [@b43]). In humans with heart failure, incomplete resolution of venous congestion is a primary cause of worsening renal function (Testani *et al*. [@b152], Guazzi *et al*. [@b61]) and is associated with poorer patient outcomes (Mullens *et al*. [@b111]). The reader can recognise the dilemma in trying to balance the negative effect of diuretic actions on arterial renal perfusion vs. the positive effect on venous renal congestion.

The RAAS, and in particular angiotensin II, precipitates and mediates oxidative and cytokine-mediated injury, inflammation and cell death (Mitani *et al*. [@b105]). The resulting endothelial dysfunction and reactive oxygen species (ROS) formation provides an important link between kidney and cardiac dysfunction ([Fig 1](#fig01){ref-type="fig"}) (Braam *et al*. [@b16]). CHF and accompanying elevated cytokine levels, reduced iron intake and absorption and suppression of angiotensin-converting enzyme (ACE) (angiotensin II is an erythropoietin secretagogue) contribute to anaemia in people (Pallazzuoli *et al*. [@b118], Chalhoub *et al*. [@b24]). Chronic inflammation is also thought to decrease sensitivity to erythropoietin and, along with kidney injury and diminished erythropoietin production, contribute to anaemia (Chalhoub *et al*. [@b24]). Diminished or ineffective circulating erythropoietin reduces haemoglobin and its antioxidant properties and contributes to CvRD~H~, through increased oxidative stress and apoptosis of kidney and cardiac cells (Silverberg *et al*. [@b143]). The importance of haemoglobin in CvRD~H~ is a subject of debate, as erythropoietin therapy used to increase haemoglobin concentration in human patients with heart failure was not associated with improved patient outcome (Jackevicius *et al*. [@b74]).

The prevalence of CvRD~H~ in dogs and cats is unknown; however, the incidence of primary kidney disease increases with age (Ross & Osborne [@b132], Polzin [@b120]). Thus, older animals with cardiovascular disease are at additional risk of developing primary kidney disease and CvRD~O~. Advances in medical therapy for CHF have resulted in improved life expectancy (Ettinger *et al*. [@b46], Haggstrom *et al*. [@b64], The BENCH Study Group [@b153], Bernay *et al*. [@b10]), thereby increasing the potential for development of primary kidney disease over time as well as cumulative exposure to potentially nephrotoxic drugs, such as diuretics and ACE inhibitors (ACEIs). ACEIs, ubiquitous in managing heart failure and hypertension, are known to be nephrotoxic at very high (70×) dosages and when administered to volume-depleted dogs (MacDonald *et al*. [@b94]). Although not known to be directly nephrotoxic, potent loop diuretics, such as furosemide, at high dosages, are associated with volume contraction and worsening kidney function, suggesting their possible role in potentiation of ACEI-induced nephrotoxicity (Steimle *et al*. [@b147], Schrier *et al*. [@b139]). Additionally, loop diuretics stimulate the RAAS system (Lantis *et al*. 2014), with well-documented pathological effects on the kidney (Francis *et al*. [@b53]). New evidence indicates that furosemide, by increasing sodium reaching the distal tubule, increases adenosine secretion, which, through vasoactive mechanisms, worsens renal function and contributes to diuretic resistance (Vallon *et al*. [@b159], Lazzarini *et al*. [@b86]). In order to reduce worsening kidney function in people with heart failure, alternatives to diuresis are being explored (Costanzo *et al*. [@b33], Givertz *et al*. [@b58]). However, there are contradictory studies, as well. A large retrospective study of human heart failure patients showed that the expected significant rise in serum creatinine with furosemide administration, although statistically significant, was very small (0 · 11 mg/dL; 9 · 7 µmol/L \[0 · 4%\]) over 5 days of hospitalisation) and explained little of the variation in serum creatinine concentration and estimated GFR (El-Refai *et al*. [@b45]). Importantly, these results agree with a smaller prospective study on the effects of intravenous furosemide at varied dosages and administration methods (Felker *et al*. [@b47]). A timely review of this material details the conflicting evidence in *virtually all* aspects of CRS development, prevention and treatment in humans (Lazzarini *et al*. [@b86]). However, the authors were able to conclude from the data available that "... acute CRS prevention and treatment might be considered among the main targets of acute HF management." and that "...loop diuretics should be administered at the minimal dose sufficient to optimize volume status, and relieve signs and symptoms of congestion, without inducing an excessive reduction in intravascular volume, which could result in hypotension and/or renal dysfunction". The dilemma of inconsistent results regarding the benefit vs. harm of loop diuretics has been recently addressed (Hanna & Deschamps [@b65]). Based on reviewing data at hand, these clinician scientists believe that a subset of CHF patients are worsened by aggressive diuresis. These authors conclude that "... congestion is at the center of acute (heart failure) syndromes. Aggressive decongestion greatly improves renal and myocardial flow and ventricular loading conditions. This allows renal function to improve enough to sustain diuresis with lower diuretic doses. This also allows the patient to tolerate lower systemic pressure without compromise of myocardial or renal perfusion. The combination of 2 particular factors predicts a poor renal tolerance of acute diuresis: (1) non-dilated left and right ventricles with a steep pressure-volume relationship (e.g. de novo acute \[heart failure\], diastolic \[heart failure\]) and (2) no or minimal peripheral edema. Patients with severe edema usually tolerate aggressive diuresis, especially if they have good plasma refill time. Conversely, in patients without severe peripheral edema and with poorly compliant, small ventricles, the preload volume is not dramatically increased but the preload pressure (left ventricular end-diastolic pressure) is increased. Therefore, these patients have pulmonary edema despite being preload volume dependent. Diuresis may be poorly tolerated in the absence of peripheral edema, leading to a large change in cardiac output and, as a result, renal failure and hypotension." They go on to further conclude that the best therapy is careful diuretic administration in conjunction with vasodilator therapy.

In dogs and cats, the existence of CvRD~H~ is indirectly supported by the observation that kidney dysfunction increases with severity of heart disease. In a retrospective study (Nicolle *et al*. [@b112]), 50% of 124 dogs with chronic valvular heart disease were azotaemic, and this finding was present in 70% of dogs with the most severe stages of disease. In dogs with severe disease, both serum BUN and creatinine were higher and GFR was lower (by nearly one-half) vs. dogs with milder heart disease. As clearly indicated by the authors, these differences in azotaemic status and GFR between mild *versus* severe heart failure stages could be related to both the effect of drugs used for the medical management of heart disease (e.g. ACEIs and diuretics) and the effect of the valvular disease itself on renal function, thus illustrating the need of further investigations to establish the direct and indirect cause-effect relationships between the progression of heart disease and the development of renal dysfunction. Similarly, in a retrospective study of cats with hypertrophic car-diomyopathy (Gouni *et al*. [@b59]), azotaemia was present in 59% of cases. Again, as stated by the authors, further prospective studies are needed to document the pathophysiological events underlying the occurrence of azotaemia in feline hypertrophic cardiomyopathy and to determine the extent to which heart and vascular diseases (and drugs used in their treatment) directly or indirectly induce kidney injury. Diseases of the vasculature are included in the proposed definition of CvRD and include disorders such as systemic hypertension (SHT) ([Fig 1](#fig01){ref-type="fig"}). Hypertension-induced glomerular damage in veterinary patients is well described (Wehner *et al*. [@b160], Surman *et al*. [@b149], IRIS Canine GN Study Group Diagnosis Subgroup *et al*. [@b73]) and among the various proposed aetiologies of CvRD ([Fig 1](#fig01){ref-type="fig"}), SHT is one of the most plausible.

### Epidemiology and pathophysiology of CvRD~K~

CvRD~K~ refers to cardiovascular injury or dysfunction emanating from a primary disease process involving the kidney. There is little direct evidence for CvRD~K~ in dogs and cats (Carlos Sampedrano *et al*. [@b21], Wilson *et al*. [@b162]). Likewise, in humans, there is more knowledge and clinical experience concerning CvRD~H~ than for CvRD~K~ (Ronco *et al*. [@b128]). There are both known and suspected negative effects of kidney disease on the cardiovascular system (Bagshaw *et al*. [@b6], Tumlin *et al*. [@b156], Ronco & Di Lullo [@b127]). For example, electrolyte abnormalities, such as hyperkalaemia, can complicate both AKI and CKD and are associated with cardiac arrhythmias (Bagshaw *et al*. [@b6]). Various drugs used for the treatment of cardiac disease, such as digoxin, enalapril and atenolol, undergo renal excretion and cause -primary kidney dysfunction, with reduced drug clearance, and can lead to signs of toxicity that include arrhythmias, hypotension and worsening myocardial function. Fluid volume and haemodynamic status are virtually always abnormal in patients with severe kidney disease (Much & Wilcox [@b110], Polzin [@b120]). Uraemic patients who are anorexic and hypodipsic and vomiting are likely to be even further volume-depleted with a resultant reduction in cardiac output. Kidney injury can also lead to systemic volume overload that contributes to congestion, especially in those animals with coexisting cardiac diseases, such as valve disease, dilated cardiomyopathy, diastolic dysfunction (hypertrophic cardiomyopathy and hypertensive heart disease) and severe anaemia (Wilson *et al*. [@b162]). The anaemia of CKD unlikely plays a significant role here, as it is typically low-grade, unless there are other factors at work (chronic inflammation, neoplasia, etc) in addition to CKD. SHT is a common sequela to CKD and can result in myocardial hypertrophy and dysfunction in both cats (Chetboul *et al*. [@b29], Henik *et al*. [@b68], Carlos Sampedrano *et al*. [@b21]) and dogs (Misbach *et al*., [@b104]). Finally, azotaemia itself may have adverse effects on cardiac myocytes (Mall *et al*. [@b98]).

### Epidemiology and pathophysiology of CvRD~O~

CvRD~O~ refers to kidney and cardiovascular injury or dysfunction emanating from either a primary disease process outside the two systems or instances in which primary kidney and cardiovascular diseases coexist (Table [1](#tbl1){ref-type="table"}). Examples of the former include sepsis and infectious diseases (Mehta *et al*. [@b102]) and an example of the latter includes an animal with primary glomerular disease and myxomatous mitral valve degeneration. Once primary kidney and cardiovascular diseases are established, CvRD~O~ pertains to the previously described interactions between the two systems that may accelerate injury to either or both. At present, these interactions are poorly defined and there is a lack of convincing, published evidence for CvRD~O~ in dogs and cats.

Clinical staging and evaluation of CvRD
---------------------------------------

The diagnosis of either a kidney disease or a cardiovascular disease requires the integration of information obtained from multiple sources. The presenting complaint, medical history and physical examination can alert the clinician to the kidney, heart or vasculature as deserving of further diagnostic testing. Blood and urine testing, non-invasive blood pressure measurement and radiographic and ultrasonographic imaging are the diagnostic tools routinely available for both kidney and cardiovascular diseases. Accurate diagnosis and staging are essential to the detection of CvRD and in designing subsequent therapeutic plans.

### Staging of Heart Disease in CvRD

> **Statement 4:** When considering the potential involvement of the heart in CvRD, the most appropriate classification system is the International Small Animal Cardiac Health Council (ISACHC) system. (No consensus; median rating, 7; range, 2--9)

This statement did not achieve consensus due to three individual rater scores that were \<5. The ISACHC system classifies animals on the basis of limited indices, such as clinical signs of heart failure and the existence or absence of cardiac hypertrophy (International Small Animal Cardiac Health Council [@b72]). One weakness of the ISACHC system is its non-specificity regarding anatomical or aetiological diagnosis. Nevertheless, alternative systems, such as the American College of Veterinary Internal Medicine system, specifically designed for dogs with myxomatous mitral valve degeneration (Atkins *et al*. [@b5]), fail to account for important cardiovascular abnormalities that can develop in CvRD, including systemic hypertension, diastolic and systolic dysfunction, arrhythmias and alterations in biomarkers. In the context of CvRD, the ISACHC or similar systems are, in isolation, incomplete means to categorise involvement of the cardiovascular system. Additional potential diagnostic and staging tools, such as cardiac imaging and biomarkers, are discussed in later sections.

### Staging of acute kidney injury and CKD in CvRD

> **Statement 5:** When considering the potential involvement of the kidney in CvRD, the most appropriate classification for acute -kidney injury and CKD are the IRIS classification systems. (Good consensus; median rating, 8.5; range, 6--9)

This statement achieved good consensus. In human and veterinary medicine, the term AKI reflects a broad spectrum of acute insults to the kidney. The IRIS systems for AKI (Table [2](#tbl2){ref-type="table"}) and CKD (International Renal Interest Society [@b71]) were deemed useful in assessing potential kidney involvement in CvRD. The IRIS systems encompass a continuum of damage from mild to severe, including several key indices of kidney function. AKI is identified by an acute rise in serum creatinine concentration, the sudden appearance of glucosuria or cylindruria or the sudden decrease in urine concentrating ability. Each grade of AKI is further subdivided based on the current nature of urine production. Other biochemical abnormalities that often accompany AKI, including microalbuminuria and increased urine protein-to-creatinine ratio, are accounted for in the IRIS system. Based on the IRIS guidelines, relatively small changes in serum creatinine concentrations can signal AKI, and the severity of AKI can fluctuate as the patient improves, worsens or transitions to CKD. The IRIS system for CKD is based on markers of kidney function, including serum creatinine and proteinuria. The CKD guidelines also incorporate systemic arterial blood pressure, which is an important pathophysiological mechanism of CRS ([Fig 1](#fig01){ref-type="fig"}) (Ronco & Di Lullo [@b127]). Thus, as opposed to existing cardiovascular staging systems, the IRIS guidelines for kidney disease were considered sufficiently complete for description of kidney injury and disease in CvRD.

Biomarkers and imaging of CvRD
------------------------------

### Biomarkers of CvRD

Biomarkers have been defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" (Biomarkers Definitions Working Group [@b11]). Ideally, any particular biomarker not only reflects the severity of the pathological process but can also be used to assess the risk of adverse events, predict outcome and guide therapy. In veterinary medicine, biomarkers generally refer to substances that can be measured in either blood or urine. The consensus group deliberated as to whether or not existing biomarkers for kidney or cardiovascular disease can be used to specifically diagnose, predict outcome or guide therapy in CvRD.

> **Statement 6:** Currently, there are no biomarkers specific for CvRD~H~. Consequences of heart disease or cardiac therapy on the kidneys should be evaluated with traditional tests of kidney function/damage as well as newer biomarkers as developed. Cardiac biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) may be useful for the establishment of heart disease or cardiac injury. (Good consensus; median rating, 7.5; range, 6--9)

This statement achieved good consensus. Biochemical and biomarker assays for assessment of kidney function are widely used and accepted (Table [3](#tbl3){ref-type="table"}). For example, serum creatinine is used to assess GFR and serum and urine albumin and total protein concentrations are used to assess glomerular permselectivity. Urine glucose and amino acid concentrations are used to assess proximal tubular function, while serum electrolytes and bicarbonate concentrations reflect the kidney\'s ability to maintain electrolyte and acid--base balance. Finally, urine specific gravity allows assessment of renal concentrating ability. The validity of these markers is well established in both primary acute and chronic kidney injury settings (Polzin [@b120]), and although their specificity to differentiate primary kidney injury vs. CvRD~H~ is untested, these traditional markers are likely adequately sensitive to detect kidney dysfunction due to CvRD~H~. The search for novel biomarkers of kidney injury and markers specific to either CRS or CvRD is a topic of considerable interest in both human and veterinary patients (Maddens *et al*. [@b96], Monti *et al*. [@b108], Tvarijonaviciute *et al*. [@b157], Cobrin *et al*. [@b30], Daure *et al*. [@b35], De Loor *et al*. [@b36], Kai *et al*. [@b78], Rossi *et al*. [@b133], Segev *et al*. [@b141]). An abbreviated list of potential markers for various aspects of kidney function is presented in Table [3](#tbl3){ref-type="table"}.

> ***Statement 7:** Currently, there are no specific biomarkers for CvRD~K~. Consequences of kidney disease on the heart (CvRD*~K~*) should be evaluated with the cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI). Biomarkers of kidney function/damage are available but need to be evaluated further in the setting of cardiac disease. (No consensus; median rating, 7; range 3--8)*.

###### 

Traditional and novel blood and urine tests to assess various kidney functions

  Kidney parameter                                          Test                                       
  --------------------------------------------------------- ------------------------------------------ ------------------
  Glomerular filtration rate                                Traditional blood and urine tests          Serum creatinine
  Plasma clearance techniques                                                                          
  Potential novel markers                                   Symmetric dimethylarginine (SDMA)          
  Glomerular permselectivity                                Traditional blood and urine tests          Serum albumin
  Urine protein: creatinine ratio                                                                      
  Microalbuminuria                                                                                     
  Potential novel markers                                   Urine immunoglobulin G                     
  Tubular damage or dysfunction                             Traditional blood and urine tests          Serum creatinine
  Serum electrolytes                                                                                   
  Serum bicarbonate                                                                                    
  Urine glucose                                                                                        
  Urine amino acids                                                                                    
  Urine protein: creatinine ratio                                                                      
  Urine specific gravity                                                                               
  Potential novel markers                                   Urine N-acetyl B-D-glucosaminidase (NAG)   
  Urine retinol-binding protein (RBP)                                                                  
  Urine gamma-glutamyl transpeptidase (GGT)                                                            
  Urine cystatin-C                                                                                     
  Urine kidney injury molecule-1 (KIM-1)                                                               
  Urine neutrophil gelatinase-associated lipocalin (NGAL)                                              
  Urinary clusterin                                                                                    

This statement did not achieve group consensus due to two individual scores that were \<5. The most common biomarker tests used to assess cardiovascular disease are N-terminal pro-B-type natriuretic peptide (NT-proBNP), B-type natriuretic peptide (BNP), N\--terminal pro-atrial natriuretic peptide (NT-proANP) and cardiac troponin I (cTnI). Although these biomarkers have been well studied in the setting of primary cardiovascular diseases such as cardiomyopathy and valve disease (DeFrancesco *et al*. [@b40], Boswood *et al*. [@b15], Connolly [@b32], Oyama *et al*. [@b117]), their validity is less well established than that of the biomarkers used for assessment of kidney function, such as creatinine and urine specific gravity. Diagnostic guidelines involving cardiac biomarkers are weakened by significant "grey-zones" that affect the ability to stratify patient populations on the basis of assay results alone (Oyama *et al*. [@b117]). The natriuretic peptides, including NT-proBNP, BNP and NT-proANP, are constitutively produced by the myocardium and help regulate plasma volume, sodium excretion and vasomotor tone in both health and disease (Potter *et al*. [@b122]). Thus, this system is inherently up- or down-regulated on a moment-to-moment basis and varies with stage of disease as well, potentially leading to erroneous conclusions. Additionally, clinically relevant individual and breed variation is recognised, both within and among healthy and diseased individuals (Kellihan *et al*. [@b79], Sjostrand *et al*. [@b144]). Moreover, few studies on cardiac biomarkers have been performed in settings applicable to CvRD~K~. In animals with apparently normal cardiac function, but with acute or chronic renal injury, serum or plasma concentrations of NT-proBNP, BNP and cTnI are increased (Lalor *et al*. [@b81], Schmidt *et al*. [@b137], Sharkey *et al*. [@b142], Miyagawa *et al*. [@b106]), as all three are at least partially dependent on kidney function for excretion. Therefore, it is difficult to know whether increased natriuretic peptide and cTn1 concentrations reflect cardiac injury, normal variation or decreased excretion. Cardiac troponin is a part of the actin-myosin complex and, in healthy individuals, serum or plasma cTnI concentration should be very low. Studies reveal that cTnI concentrations are increased in dogs and cats with primary and secondary cardiac disease and predict clinical outcome (Oyama & Sisson [@b116], Fonfara *et al*. [@b51], Hezzell *et al*. [@b69], Langhorn *et al*. [@b83]). This suggests that cTnI might be able to detect subclinical cardiac injury due to CvRD~K~; however, interpretation of cTnI assay is clouded by lack of information regarding the time course and magnitude of cTnI release in many disease conditions.

### Imaging in CvRD

> **Statement 8:** Thoracic radiography is recommended to assess the presence or absence of congestive heart failure, and echocardiography is recommended to assess cardiac morphology, lesions, and to estimate relevant haemodynamic parameters. (Strong consensus; median rating, 8; range, 7--9)

This statement achieved strong consensus. Diagnostic imaging plays an important role in the assessment of cardiac function. Radiographic and ultrasound imaging modalities provide morphological expressions of the anatomy and function. These findings and complementary data are derived from history, physical examination, electrocardiography and laboratory analyses of blood and urine. Together, this combination of data allows determination of the presence, cause, severity and consequences of heart disease. Typically, the objective of cardiothoracic radiographic examination is to detect changes in the cardiac silhouette, vascular structures and lung parenchymal pattern, −ultimately determining if there are signs of cardiac disease or CHF. Echocardiography is used to assess cardiac morphology and function. Doppler echocardiography, including spectral Doppler, color flow Doppler, tissue Doppler and more advanced modalities such as strain, strain rate and 2D speckle tracking, provides specific information about the velocity and direction of blood flow and myocardial motion (Chetboul [@b27], Chetboul &Tissier [@b28]). Longitudinal changes in radiographic and echocardiographic indices help determine morbidity and predict mortality in dogs and cats with heart disease (Lord *et al*. [@b92], Reynolds *et al*. [@b124]). Thus, radiographic and echocardiographic imaging modalities represent two cornerstones of cardiac diagnostic examination. The reader is referred to several excellent reviews of cardiothoracic radiographic and echocardiographic interpretation for more information (Thomas *et al*. [@b154], Buchanan & Bucheler [@b20], Litster & Buchanan [@b90], Guglielmini *et al*. [@b62], Chetboul [@b27], Schober 2010, Chetboul & Tissier [@b28]).

> **Statement 9:** Renal imaging is recommended to improve diagnosis, prognosis and guide potential therapies in CvRD. Conventional abdominal radiographs and ultrasound are recommended to help detect morphological abnormalities and determine underlying aetiology. (Good consensus; median rating, 8; range, 6--9)

This statement achieved good consensus. Various imaging modalities are available to assess the kidney and urinary system. Plain orthogonal radiographic examination, in particular, the ventrodorsal view, allows determination of kidney size and number and may provide evidence of unilateral or bilateral abnormalities or differences in kidney size, shape and position, as well as detection of presence of radiodense uroliths (Rivers & Johnston [@b126], Polzin [@b120], Bartges [@b7]). Ultrasonic examination of the kidneys and urinary tract allows visualisation of renal parenchymal abnormalities, renal pelvic and ureteral dilation, renal blood flow abnormalities, infarcts, cysts, mineralisation and uroliths and helps achieve a diagnosis of pyelonephritis, lymphoma or ethylene glycol toxicosis (Rivers & Johnston [@b126], Lamb [@b82], Debruyn *et al*. [@b37]). The biggest limitation to ultrasonic evaluation is its lack of sensitivity to minor alterations in the anatomy of renal pelvises and ureters (Lamb [@b82]). Contrast studies, such as the excretory urogram, or more advanced techniques, such as computerised tomography or magnetic resonance imaging with contrast, may provide additional information regarding the patency of the urinary system and the presence of abnormalities (Ohlerth & O\'Brien [@b114], Chang *et al*. [@b25], Fonseca-Matheus *et al*. [@b52], Schmidt *et al*. [@b138]). The reader is referred to several excellent reviews of kidney and urinary tract imaging for additional information (Rivers & Johnston [@b126], Lamb [@b82], Debruyn *et al*. [@b37]).

### Systemic blood pressure measurement in CvRD

> **Statement 10:** As the kidney and heart are two organs at risk for damage due to systemic hypertension, and as kidney disease is often associated with systemic arterial hypertension, systemic arterial blood pressure should be systematically monitored in both kidney and cardiovascular diseases. (Good consensus; median rating, 8; range, 5--9)

This statement achieved good consensus. One of the best-described interactions between the kidney and cardiovascular system involves their intimate roles in regulation of arterial blood pressure. SHT represents the best example of a mechanism by which CvRD~H~, CvRD~K~ and CvRD~O~ may occur. Because hypertension negatively affects both organ systems, blood pressure measurement is routinely recommended in patients with kidney or cardiovascular disease, and the reader is referred to several excellent reviews regarding the measurement of blood pressure in dogs and cats (Brown *et al*. [@b18], Syme [@b150], Stepien [@b148]). SHT is also commonly associated with diseases other than kidney disease, such as hyperadrenocorticism, hyperaldosteronism, phaeochromocytoma, hyperthyroidism, hypothyroidism, canine diabetes mellitus and canine acromegaly (Brown *et al*. [@b18]). SHT is likewise associated with certain therapeutic agents, such as glucocorticoids, mineralocorticoids, erythropoietin and phenylpropanolamine (Brown *et al*. [@b18]). SHT can also be stress-induced (i.e. white-coat hypertension) or may occur in the absence of other identifiable disease (i.e. idiopathic, primary or "essential" hypertension) (Belew *et al*. [@b9], Marino *et al*. [@b99]). As in humans, SHT in dogs and cats is a -potential cause of -irreversible lesions in cardiac, vascular, renovascular, ocular and central nervous system tissues. Systolic pressure \>160 mmHg indicates progressive risk of end- or target-organ damage (International Renal Interest Society [@b71]). With regard to the canine kidney, SHT can result in increased rate of renal injury, proteinuria, decreased GFR, increased incidence of uraemic crisis and worsened mortality. (Jacobs *et al*. [@b75]) In the cat, the causal relationship between hypertension and kidney disease is less clear. It is known that hypertension is a risk factor for proteinuria, which, in turn, is a risk factor for worsening kidney disease (Syme *et al*. [@b151], Jepson *et al*. [@b76], Chakrabarti *et al*. [@b22]). In a correlative study of laboratory variables and pathological lesions in the kidneys of cats with CKD, proteinuria was associated with interstitial fibrosis and glomerular hypertrophy, whereas higher time-averaged systolic blood pressure was associated with glomerulosclerosis and hyperplastic arteriosclerosis (Chakrabarti *et al*. [@b23]). Cardiovascular injury secondary to SHT is well accepted in humans (Frohlich *et al*. [@b56], Drazner [@b42]) and includes left ventricular concentric hypertrophy, arrhythmia, haemorrhage, vascular and myocardial fibrosis and remodelling, development of aortic insufficiency, mainly diastolic but also systolic dysfunction, and heart failure. Controlled studies are lacking in dogs and cats, but observational studies have described several left ventricular hypertrophic patterns (Snyder *et al*. [@b146], Chetboul *et al*. [@b29], Henik *et al*. [@b68], Carlos Sampedrano *et al*., 2006), reversal of left ventricular hypertrophy with blood pressure control (Snyder *et al*. [@b146]), retinal vasculopathy (Maggio *et al*. [@b97]), aortic -dissection and aortic insufficiency related to proximal aortic dilation (Wey & Atkins [@b161], Misbach *et al*. [@b104]) and heart failure (Wey & Atkins [@b161], Chetboul *et al*. [@b29]). -Additionally, two\--dimensional tissue Doppler imaging studies have demonstrated that SHT in both cats and dogs is associated with -diastolic and, to a lesser extent, systolic dysfunction, independent of the presence of myocardial hypertrophy (Carlos Sampedrano *et al*. 2006, Misbach *et al*. [@b104]).

The reported prevalence of SHT in dogs and cats with CKD varies considerably, depending on the population selected, the stage of kidney disease and the blood pressure measuring technique employed, but CKD is assuredly present in a considerable percentage of the population at risk for SHT (Brown *et al*. [@b18]). SHT is estimated to occur in 60--90% of dogs and 20--65% of cats with kidney disease (Stepien [@b148]). The relationship of SHT with mitral valve disease in dogs is incompletely understood, and blood pressure varies by stage of disease (Petit *et al*. [@b119]). The minimum database in animals with SHT should include a CBC, serum biochemistry panel, serum thyroxine concentration, urinalysis and abdominal ultrasound (Brown *et al*. [@b18]). Ruling out endocrine or other secondary causes of SHT may require additional disease-specific assays.

Disorders that cause systemic *hypotension* can also cause kidney and cardiovascular injury. Hypotension, due to severe volume depletion, low cardiac output or collapse of systemic vascular resistance, reduces tissue perfusion and GFR and activates maladaptive neurohormonal responses (Morales *et al*. [@b109]). Systemic hypotension, defined as systolic pressure \<90 mmHg, has been associated with acute heart failure, occurring in 16% of dogs and cats during hospitalisation (Goutal *et al*. [@b60]). In a study of dogs with mitral valve disease, systolic BP was inversely correlated to clinical severity of disease. This indicates the potential for a cardiac disease-related and/or treatment-induced vascular complication (hypotension). Kidney damage would occur if hypotension is severe enough to produce renal under-perfusion. (Petit *et al*. [@b119]). Treatment of SHT is discussed under Management of CvRD.

### Management of CvRD

Treatment of CvRD is challenging, as the treatment for kidney disease often relies upon fluid therapy and close attention to the amount and quality of protein and phosphorous intake (Roudebush *et al*. [@b134], Monaghan *et al*. [@b107], Polzin [@b121]). In contrast, animals with heart failure typically undergo diuresis and receive protein supplementation, especially in those with signs of congestion (pulmonary oedema or third space effusions) and/or cardiac cachexia, respectively (Atkins *et al*. [@b5], Borgarelli & Haggstrom [@b13]). Also important to the management of CvRD are an understanding of the tendency for azotaemia to develop in animals receiving diuretics, the benefits and risks of ACEI in the setting of concurrent kidney and cardiovascular disease and the potential influence of SHT on both organ systems (Nicolle *et al*. [@b112], Atkins *et al*. [@b5], Brewer *et al*. [@b17]). Thus, both the heart and kidney are affected by abnormal intravascular fluid volume, systemic blood pressure and commonly employed treatments such as diuretics, vasodilators and supplemental fluids used to correct these imbalances. These factors potentially affect the interaction between these two organ systems (DeFrancesco [@b38]).

The clinical staging and management of heart failure (Borgarelli *et al*. [@b14], Atkins *et al*. [@b5], Ferasin [@b48], Atkins & Haggstrom 2012, DeFrancesco [@b39]), AKI and CKD (Lees *et al*. [@b87], Roudebush *et al*. [@b134], Polzin [@b120], [@b121], Ross [@b131], Vaden [@b158], Bartges [@b7], Monaghan *et al*. [@b107]) have been extensively described. In brief, heart failure is the condition wherein the diseased heart fails to provide adequate cardiac output or can only do so in the presence of elevated venous -filling pressures and the risk of congestion (Colluci & Braunwald [@b31]).

Treatment of acute and chronic CHF involves the use of diuretics, including furosemide and hydrochlorothiazide (Atkins *et al*. [@b5], Goutal *et al*. [@b60], Atkins & Haggstrom 2012); vasodilators, including ACEI (Atkins *et al*. [@b5], Goutal *et al*. [@b60], Atkins & Haggstrom 2012), amlodipine (Quinones *et al*. [@b123], Snyder *et al*. [@b146]), diltiazem (Gelzer *et al*. [@b57]), nitroglycerin, hydralazine and nitroprusside (Atkins [@b3], Atkins & Haggstrom 2012); neurohormonal blocking agents, including ACEI, spironolactone (Atkins *et al*. [@b5]) and beta blockers, such as atenolol and propranolol (Rush *et al*. [@b136], Goutal *et al*. [@b60]); and positive inotropes such as digoxin**,** dobutamine and pimobendan (Atkins *et al*. [@b5], Goutal *et al*. [@b60], MacGregor *et al*. [@b95], Atkins & Haggstrom 2012). AKI and CKD are conditions wherein the diseased kidney fails to adequately excrete waste products and to maintain fluid volume and electrolyte balance, resulting in volume and electrolyte abnormalities, azotaemia and clinical signs of uraemia, when severe.

Treatment of AKI and CKD involves a combination of parenteral fluids, the infrequent use of diuretics for treatment of volume overload and hyperkalaemia, antihypertensive agents, ACEI, gastrointestinal protectants, alkalizing agents, erythropoiesis-stimulating agents, phosphate binders and dietary adjustment. A key aspect to the treatment of both AKI and CKD is maintenance of adequate intravascular volume and pressure to allow sufficient renal perfusion, while avoiding fluid overload and electrolyte imbalance. Contrarily, a major goal in the treatment of CHF is reduction of intravascular volume and hydrostatic pressure, through the use of diuretics and other offloading therapies. Thus, essential to both cardiac and kidney diseases is the need to restore and maintain normal fluid balance, which is often a particularly difficult aspect of therapy (DeFrancesco 2008).

The pharmacological management of cardiovascular and renal diseases contributes to CvRD. Excessive reduction in vascular volume in cases of CHF or excessive increases in vascular volume in cases of AKI or CKD can lead to adverse effects in the other organ system. Achieving the correct balance is, of course, more difficult when the heart and kidneys are concomitantly dysfunctional. Treatment of CvRD involves the recognition and simultaneous, frequent evaluation of subtle changes in kidney or heart function and an understanding of how the pathophysiology of one disease can interact with and impact the function of the other. An important aspect of managing CvRD is to treat the primary cause of clinical signs, while attempting to minimise clinically relevant worsening of the function of the other organ. Management guidelines for CvRD are almost exclusively based on theory and expert opinion, as clinical trials specific to CvRD are lacking.

### Management of CvRD~H~

> **Statement 11:** Unstable CvRD~H~, such as in instances of acute CHF, typically requires hospitalisation to restore or improve cardiac function and to alleviate congestive or low output signs while simultaneously evaluating risk of kidney dysfunction. Standard acute CHF therapy that includes diuretics, ACEI, vasodilators and positive inotropes might need to be adjusted based on frequent assessment of hydration, renal function biomarkers, electrolytes, blood pressure, body weight and urine output. (Strong consensus; median rating, 8; range, 8--9)

This statement achieved strong consensus. In cases of CVRD~H~, the therapeutic margin is small as the use of diuretics and ACEI can have adverse effects on renal function and overly aggressive diuresis with excessive dehydration should be avoided. Strategies to minimise the development of azotaemia during treatment of acute CHF include reducing the total daily dosage (dosage and/or frequency of administration) of parenteral diuretics, use of venous or arterial vasodilators to augment reduction of preload and afterload and use of pimobendan or intravenous dobutamine infusion to increase cardiac output and kidney perfusion. A small proportion of clinicians withhold or minimise the use of ACEI during in-hospital treatment for acute CHF, as diuretic-induced volume depletion might increase the risk for ACEI-induced renal injury (Atkins *et al*. [@b5]). If ACEIs are withheld or withdrawn during the acute phase, they are typically (re)introduced once the initial episode of acute CHF is resolved, and the animal is discharged to home care. In cases of severe volume depletion, (re)introduction of diuretics or ACEIs should occur only after the animal\'s hydration status has improved or at the recurrence of clinical signs of congestion. One potential therapeutic strategy involving the various ACEIs, such as enalapril, benazepril, ramipril and imidapril, is the administration of a dosage at the lower end of the recommended range followed by evaluation of hydration status and renal function before a decision whether to titrate either drug to the higher end of the dosage range. Free choice of water should always be provided to such patients, unless vomiting or diminished mental status dictates otherwise. In severely dehydrated animals or in those with substantial azotaemia or uraemia following diuretic therapy, intravenous or subcutaneous fluids, with consideration as to a particular fluid\'s sodium and potassium content, should be carefully administered. The use of feeding tubes should be considered in anorexic animals to provide both nutrition and sodium-free hydration. Anti-aldosterone agents such as spironolactone are often prescribed in the chronic phases of CHF treatment (Bernay *et al*. [@b10]), and the potential for additional beneficial effects such as reduction of cardiac, renal and vascular remodelling in patients with CvRD merits further investigation (Ovaert *et al*. [@b115]). Serum potassium concentrations should be closely monitored -- especially when spironolactone is used in conjunction with ACEI or in the setting of renal dysfunction.

### Management of CvRD~K~

> ***Statement 12:** Unstable CvRD*~K~*, such as in instances of acute kidney injury (AKI), typically requires hospitalisation to improve renal function and to restore fluid and electrolyte balance while simultaneously evaluating the risk of cardiac dysfunction. In addition to standard management of AKI, particular attention should be directed towards 1) appropriate fluid, diuretic and/or antihypertensive treatment based on hydration status; these therapies are aimed at restoration and maintenance of normal fluid balance and blood pressure while avoiding sodium and fluid overload and 2) re-evaluation of concurrent cardiac medications and possible dosage adjustment. (Strong consensus; median rating, 8; range, 7--9)*

This statement achieved strong consensus. This agreement stems from the clinical experiences of the authors, in which diuretic use is recognised as a double-edged sword, saving lives by reducing congestion, but, conversely, being overused in coughing dogs or dyspneic cats with or at risk of developing AKI. Since the diagnosis of CHF can be elusive, these pets may undergo diuresis appropriately, when suffering from CHF, or inappropriately when not. The authors also note that potent loop diuretics, usually furosemide, are sometimes prescribed at inappropriately high dosages for extended periods, with harmful drying of airway secretions and/or worsening azotaemia.

In cases with clinically significant dehydration, parenteral fluid replacement is often provided in an effort to regain -appropriate fluid balance and urine production in patients without frank heart failure. Even in the absence of clinical signs of heart failure, fluid supplementation should be closely monitored to avoid precipitation of congestion and discontinued if respiratory signs are noted or if weight gain becomes excessive. In instances where signs of over-hydration and congestion occur, fluid administration should be discontinued and the addition of diuretics considered.

Patients with CvRD~K~ might necessitate a cautious and stepwise approach to fluid replacement or maintenance with a selection of a fluid type relatively low in sodium, along with careful monitoring of body weight, respiratory rate and effort, arterial blood pressure and for development of jugular venous distension or ascites. Resting (i.e. non-panting) respiratory rates \>40 breaths per minute have been shown to be a sensitive indicator of early pulmonary congestion (oedema) (Schober *et al*. [@b140], Ohad *et al*. [@b113], Ljungvall *et al*. [@b91]). Inadvertent fluid overloading puts additional stress on the cardiovascular system and increases the risk of congestion. With the exception of cases of systemic hypotension, dopamine is not indicated for management of AKI due to lack of proven efficacy and potential for adverse side effects, such as worsening of renal function, arrhythmias and sinus tachycardia. (Chertow *et al*. [@b26], Lauchske *et al*. 2006, Wohl *et al*. [@b163]) The use of renal replacement therapies (such as haemodialysis and ultrafiltration) that enable fine control over intravascular volume in CvRD~K~ is intriguing (Acierno [@b1], Cowgill [@b34], Eatroff *et al*. [@b44]), but requires additional study.

### Important aspects of managing all forms of CvRD

> **Statement 13:** In addition to specific management strategies for CvRD~H~ or CvRD~K~, particular attention should be directed towards the following when managing any form of CvRD: 1) identification and treatment of elevated blood pressure as per IRIS recommendations; 2) stepwise titration of dosages of diuretics, ACEI, inotropes and/or fluids with frequent monitoring of renal function, body weight, hydration, electrolyte status, and systemic blood pressure (i.e. performed and rechecked within 3--5 days following initiation or dose adjustment of these drugs); 3) proper nutrition, with respect to reduced dietary sodium and phosphate and appropriate protein and caloric intake. (Strong consensus; median rating, 8; range, 8--9)

This statement achieved strong consensus. In dogs and cats with CvRD, the goal is to maintain systolic blood pressure \<160 mmHg in an attempt to prevent or minimise target-organ damage (International Renal Interest Society [@b71]). As blood pressure increases to above 160 mmHg, the risk to target organs increases and treatment is recommended, with or without evidence of target-organ damage. In both dogs and cats, expert opinion advocates for dietary sodium restriction with concurrent pharmacological therapy (Brown *et al*. [@b18], International Renal Interest Society [@b71]). In dogs, the first choice therapy is an ACEI, which is titrated to effect while monitoring renal function. In cats, the first choice therapy is the calcium channel blocker amlodipine (International Renal Interest Society [@b71]). In cases of refractory SHT, combination therapy with ACEI and amlodipine is useful in both species. Measuring systemic blood pressure accurately in dogs and cats requires careful attention to the equipment and technique. This and a more detailed description of therapy is the subject of several excellent reviews (Brown *et al*. [@b18], Syme [@b150], Stepien [@b148]).

In animals with any form of CvRD, stepwise changes in diuretics or fluids are performed with care and with concurrent monitoring of hydration, renal function and resting respiratory rate. Veterinarians usually administer intravenous or subcutaneous fluids to dogs and cats with anorexia, with urinary tract disease and during anaesthesia in an attempt to maintain hydration and renal perfusion. While potentially useful, fluid administration should be performed with caution, using low-sodium parenteral fluids or sodium-free enteral hydration via feeding tube, especially in the face of underlying heart disease or SHT. Any fluid type can precipitate CHF or hypertensive crisis if administered too rapidly or in excessive volumes. During treatment, veterinarians and, when possible, owners, should monitor the animal\'s renal function, respiratory rate and effort, food and water intake, body weight and urine output. Changes in these parameters often signal significant changes in hydration status, worsening of disease or need for medication adjustments. In instances of severe CvRD, in which treatment balance is difficult to achieve, referral to a secondary or tertiary hospital should be considered.

Another important consequence of CvRD is the alteration of drug pharmacokinetics and pharmacodynamics due to impaired heart or kidney function. For example, furosemide requires active secretion across proximal renal tubular cells in order to reach the lumen and its site of co-transporter binding, so that decreased renal perfusion or tubular injury decreases the expected diuretic response (Rose *et al*. [@b130]). Cardiac drugs primarily excreted by the kidneys, such as digoxin, enalapril and atenolol, may require dosage adjustments in animals with AKI or CKD (Fleet *et al*. [@b49], Kitagawa *et al*. [@b80], Merrett [@b103], Quinones 1996, Toutain 2000). In patients with CvRD and metabolic acidosis or hypoproteinaemia, dosages of drugs that are highly protein bound, such as pimobendan or digoxin, may need to be adjusted. Finally, drug dosages may change for a variety of other reasons. Cardiac cachexia can result in a reduction in dosage requirements as the volume of distribution or drug protein binding is altered necessitating careful modification of the drug dosage with disease progression (Freeman [@b54]). Likewise, abnormal protein catabolism in cachectic patients may increase serum BUN concentrations, worsening azotaemia. In animals with persistent congestion, the presence of ascites or pleural effusion alters the volume of drug distribution and dosing on lean body weight is preferred.

Ensuring proper nutrition is an important component of managing CvRD. Moderately sodium-restricted diets are appropriate for both kidney and cardiovascular diseases and reduced phosphorus diets are important in kidney disease (Rush *et al*. [@b135], Atkins *et al*. [@b5], Polzin [@b120]). As previously mentioned, dogs with chronic heart disease may lose muscle mass and body condition, thus confirming that adequate protein and caloric intake is an important goal. In animals with CvRD, this need is -counterbalanced by the detrimental effect of high protein intake on azotaemia; therefore, careful dietary planning with the support of a veterinary nutritionist or internist might be helpful. Dietary supplements, such as omega-3 fatty acids, are occasionally used in animals with CvRD (Freeman *et al*. [@b55], Smith *et al*. [@b145], Roudebush *et al*. [@b134], Polzin [@b120]), both as antioxidants and appetite stimulants, but their safety and efficacy have not been rigorously demonstrated (Lenox & Bauer [@b88]).

CONCLUSION
==========

Although still very early, there is growing evidence indicating that the pathological states, CRS and CvRD, respectively, may be important in both humans and animals. While some aspects of CvRD clearly exist in dogs and cats, the existence of others is merely speculative. There is clearly much to do in identifying, proving and understanding this subject. This consensus statement is meant to increase the awareness of and codify the definition, classification and means of identification and provide provisional information on management of CvRD. Additionally, this manuscript aims to stimulate and provide a framework for research and communication on CvRD and to encourage collaborative studies involving cardiologists and nephrologists.

The CRS Consensus Group is made up of a diverse group of experts in veterinary cardiology and nephrology, whose efforts resulted in 11 (of 13 proposed) CvRD consensus statements for dogs and cats. The authors recommend that this consensus document be modified, as new information regarding CvRD is available. During their discussions and deliberations, the authors were continuously reminded that the heart, vessels and kidney are inexorably linked, not only anatomically but also by principles at the foundations of physiology, pathology and medicine, and that consideration of a single cardiovascular-renal axis has great merit. The authors hope that this manuscript stimulates interest; advances knowledge of CvRD, its existence and importance; and ultimately contributes to the ability of veterinarians to successfully manage dogs and cats with, or at risk for, this condition.

The modified Delphi methodology, used to build the consensus and develop guidelines for CvRD, provided a formal, predictable and objective scaffold for this project. This method or others like it warrant consideration for developing future consensus statements for veterinary medicine.
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